

Freedom of Information Request: Our Reference CTMUHB_09_24

You asked:

Q1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

- **Abatacept [Orencia]**
- **Adalimumab [Humira]**
- **Adalimumab Biosimilars**
- **Apremilast [Otezla]**
- **Baricitinib [Olumiant]**
- **Bimekizumab [Bimzelx]**
- **Certolizumab [Cimzia]**
- **Etanercept [Enbrel]**
- **Etanercept Biosimilars**
- **Filgotinib [Jyseleca]**
- **Golimumab [Simponi]**
- **Guselkumab [Tremfya]**
- **Infliximab [Remicade]**
- **Infliximab Biosimilars**
- **Ixekizumab [Taltz]**
- **Risankizumab [Skyrizi]**
- **Rituximab [MabThera]**
- **Rituximab Biosimilars**
- **Sarilumab [Kevzara]**
- **Secukinumab [Cosentyx]**
- **Tocilizumab [Ro Actemra]**
- **Tocilizumab Biosimilars**
- **Tofacitinib [Xeljanz]**
- **Upadacitinib [Rinvoq]**
- **Ustekinumab [Stelara]**

Please find below a table populated with the information Medicines Management are able to provide in relation to question 1. The period the data relates to is the 1st October 2023 to 31st December 2023, the latest 3 months available.

Please note - Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This

exemption is absolute and therefore there is no requirement to apply the public interest test.

Medicine	Number of patients
Abatacept [Orencia]	55
Adalimumab [Humira]	83
Adalimumab Biosimilars	362
Apremilast [Otezla]	70
Baricitinib [Olumiant]	38
Bimekizumab [Bimzelx]	**
Certolizumab [Cimzia]	59
Etanercept [Enbrel]	25
Etanercept Biosimilars	295
Filgotinib [Jyseleca]	6
Golimumab [Simponi]	62
Guselkumab [Tremfya]	**
Infliximab [Remicade]	**
Infliximab Biosimilars	22
Ixekizumab [Taltz]	21
Risankizumab [Skyrizi]	0
Rituximab [MabThera]	**
Rituximab Biosimilars	33
Sarilumab [Kevzara]	**
Secukinumab [Cosentyx]	89
Tocilizumab [Ro Actemra]	90
Tocilizumab Biosimilars	0
Tofacitinib [Xeljanz]	10
Upadacitinib [Rinvoq]	15
Ustekinumab [Stelara]	11

Q2. Could you please provide the numbers of patients treated for Axial Spondyloarthritis (axSpA) ONLY in the last 3 months with the following drugs.

- **Adalimumab [Humira]**
- **Adalimumab Biosimilars**
- **Certolizumab [Cimzia]**
- **Etanercept [Enbrel]**
- **Etanercept Biosimilars**
- **Golimumab [Simponi]**
- **Infliximab [Remicade]**
- **Infliximab Biosimilars**
- **Ixekizumab [Taltz]**
- **Secukinumab [Cosentyx]**
- **Tofacitinib [Xeljanz]**
- **Upadacitinib [Rinvoq]**

We can confirm that the Health Board does not centrally record this information. The information you require would be recorded within an individual

patient's health record as part of their ongoing care. To provide you with this information, would require a manual trawl and significantly exceed the 18 hours time and £450 cost limit set out within Section 12 of the Freedom of Information Act.